The *Journal for Immunotherapy of Cancer (JITC)* is the leading open access journal in tumor immunology and cancer immunotherapy.

**JITC** aims to enrich communication and advance scientific understanding in this rapidly evolving field. Content includes high-quality original research articles and authoritative reviews written by recognized, leading scientists and clinicians.

**Primary readership:** Scientists, academicians, researchers, clinicians and government representatives who work in oncology and/or immunology.

**JITC** is the official journal of the Society for Immunotherapy of Cancer, representing more than 3,000 members from 31 medical specialties in 40 countries around the world.

### At a glance

<table>
<thead>
<tr>
<th>Year established:</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Impact factor:</td>
<td>13.751*</td>
</tr>
<tr>
<td>Rank</td>
<td>15/242 in Oncology 8/162 in Immunology*</td>
</tr>
<tr>
<td>Editor-in-Chief:</td>
<td>Pedro Romero, MD</td>
</tr>
<tr>
<td>Online Frequency:</td>
<td>Continuously published</td>
</tr>
</tbody>
</table>

### Digital traffic

<table>
<thead>
<tr>
<th>Category</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global visitors*</td>
<td>888k</td>
</tr>
<tr>
<td>Global page views*</td>
<td>1.3M</td>
</tr>
<tr>
<td>U.S. visitors*</td>
<td>335k</td>
</tr>
<tr>
<td>U.S. page views*</td>
<td>473k</td>
</tr>
<tr>
<td>e-Newsletter recipients</td>
<td>10k</td>
</tr>
<tr>
<td>Global eTOC recipients</td>
<td>3k+</td>
</tr>
</tbody>
</table>

* Source: Google Analytics, July 2020 - June 2021

* Source: 2020 Journal Citation Reports®, Clarivate Analytics, 2021
ADVERTISING OPPORTUNITIES

Online advertising options available, as well as tailored packages including:

- Reprints and ePrints
- Email table of content (eTOC) alerts
  - 3,000+ recipients
  - Includes opted-in SITC members
- e-Newsletter advertising
  - Sponsor an authentic JITC content email
  - Sent to opted-in SITC members and U.S. medical oncologists and immunologists

**JITC online offers the opportunity to target your products through geo-targeted, online advertising. There are a full range of digital opportunities available.**

### DIGITAL ADVERTISING RATES

<table>
<thead>
<tr>
<th>Pixels</th>
<th>Rate</th>
<th>Minimum charge</th>
<th>Specifications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Website mobile banner</td>
<td>$81 per 1,000 impressions</td>
<td>$2,025 for 25,000 impressions</td>
<td>File type GIFs (animated preferred) and Rich Media accepted, subject to production clearance. File size up to 50k. Deadline to receive materials 5 working days prior to deployment.</td>
</tr>
<tr>
<td>Website leaderboard</td>
<td>$81 per 1,000 impressions</td>
<td>$4,050 for 50,000 impressions</td>
<td></td>
</tr>
<tr>
<td>Website MPU (Mid page unit)</td>
<td>$86 per 1,000 impressions</td>
<td>$2,150 for 25,000 impressions</td>
<td>JPEG or GIF accepted</td>
</tr>
<tr>
<td>eTOC alert leaderboard</td>
<td>Please contact Jim Cunningham at <a href="mailto:jcunningham@cunnasso.com">jcunningham@cunnasso.com</a> for the latest email advertising rates.</td>
<td></td>
<td>Please note: Advertisements are accepted subject to availability and BMJ approval.</td>
</tr>
<tr>
<td>eTOC alert MPU</td>
<td>Please contact Jim Cunningham at <a href="mailto:jcunningham@cunnasso.com">jcunningham@cunnasso.com</a> for the latest email advertising rates.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>e-Newsletter</td>
<td>Please contact Jim Cunningham at <a href="mailto:jcunningham@cunnasso.com">jcunningham@cunnasso.com</a> for the latest email advertising rates.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
TARGETED SOLUTIONS

Hurry! Limited opportunities available.

E-NEWSLETTER SPONSORSHIP

Send new research to your audience through a monthly e-newsletter sponsorship.

Content is selected by the Editorial team and sent to specialty-specific U.S. physicians. 30% average open rate.

- Annual sponsorships available
- 10k+ recipients, including:
  - eTOC registrants
  - Oncology and immunotherapy specialists
  - Opted-in members of the Society for Immunotherapy of Cancer
- Two ad slots per e-newsletter:
  - 600 x 90: animation accepted
- Twelve-month, exclusive sponsorship available
  - Please contact Jim Cunningham at jcunningham@cunnasso.com for more details.
TARGETED SOLUTIONS

Hurry! Limited opportunities available.

DIGITAL ROADBLOCK PACKAGE

This exclusive opportunity gives your ads 100% share-of-voice on the website and within the email table of content (eToc) alerts for an entire month.

- Banner ads
- eTOC alerts

For more information on advertising, and to discuss your campaign requirements, please contact:

JIM CUNNINGHAM
National Accounts Manager
(201) 767-4170 office
(201) 394-4426 cell
jcunningham@cunnasso.com

Clinical/translational cancer immunotherapy

Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA
Pedro Bacaeta, Najma Aqwal, Roberto Navarrete-Vazquez et al. (2022-08-13)
10.1101/2022-08-13

Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects
Jaila Delahousse, Charles Skarbeck, Melanie Desbois et al. (2022-08-13)
10.1101/2022-08-13

Subtype and grade-dependent spatial heterogeneity of T-cell infiltration in pediatric glioma
M Hope Robinson, Jovan Vukas, Abhi Kaurkhal et al. (2022-08-13)
10.1101/2022-08-13

Oncolytic and local immunotherapy

Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclomodulin pre-conditioning
Jonathan G Pol, Matthew J Albright, Kyle B Stephenson et al. (2022-08-13)
10.1101/2022-08-13